Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Tetsuhito Muranaka"'
Autor:
Hiroshi Nakatsumi, Yoshito Komatsu, Tetsuhito Muranaka, Satoshi Yuki, Yasuyuki Kawamoto, Kazuaki Harada, Masayoshi Dazai, Miki Tateyama, Yusuke Sasaki, Takuto Miyagishima, Yasushi Tsuji, Masaki Katagiri, Michio Nakamura, Susumu Sogabe, Kazuteru Hatanaka, Takashi Meguro, Tomoe Kobayashi, Atsushi Ishiguro, Osamu Muto, Yoshiaki Shindo, Masahito Kotaka, Takayuki Ando, Ryo Takagi, Naoya Sakamoto, Yu Sakata
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe first-line chemotherapy for patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies. Whe
Externí odkaz:
https://doaj.org/article/aab8f05946ed4eb79d1f6def13b45094
Autor:
Yasuyuki Kawamoto, Yoshito Komatsu, Satoshi Yuki, Kentaro Sawada, Tetsuhito Muranaka, Kazuaki Harada, Hiroshi Nakatsumi, Hiraku Fukushima, Atsushi Ishiguro, Masayoshi Dazai, Kazuteru Hatanaka, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, Susumu Sogabe, Yoshimitsu Kobayashi, Takuto Miyagishima, Kota Ono, Naoya Sakamoto, Yuh Sakata
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-6 (2017)
Abstract Background In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment. Nab-paclitaxel was developed for chemothera
Externí odkaz:
https://doaj.org/article/5eb50e1555324189bdb9aa9a907bc4f0
Autor:
Toshiki Masuishi, Hiroya Taniguchi, Yoshito Komatsu, Takeshi Kawakami, Yasuyuki Kawamoto, Shigenori Kadowaki, Yusuke Onozawa, Tetsuhito Muranaka, Masahiro Tajika, Hirofumi Yasui, Hiroshi Nakatsumi, Satoshi Yuki, Kei Muro, Katsuhiro Omae, Kentaro Yamazaki
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Background Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear. Pretreatment tumour growth rate (TGR) is associated with r
Externí odkaz:
https://doaj.org/article/cac10407b1fe46c5840f488120d1fd8a
Autor:
Takahiko Kobayashi, Junich Ishida, Yuichi Shimizu, Hiroshi Kawakami, Goki Suda, Tetsuhito Muranaka, Yoshito Komatsu, Masahiro Asaka, Naoya Sakamoto
Publikováno v:
Tumor Biology, Vol 39 (2017)
RNA-binding motif 5 is a putative tumor suppressor gene that modulates cell cycle arrest and apoptosis. We recently demonstrated that RNA-binding motif 5 inhibits cell growth through the p53 pathway. This study evaluated the clinical significance of
Externí odkaz:
https://doaj.org/article/4a4c89bc44bc4694a468243b39a8d0fa
Autor:
Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Kazuaki Harada, Shintaro Nakano, Rika Saito, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Publikováno v:
Supportive Care in Cancer. 30(6):5351-5359
Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::261c2ba1015e946b80516fcaac246c93
http://hdl.handle.net/2115/85674
http://hdl.handle.net/2115/85674
Autor:
Kazuaki Harada, Takahiro Yamamura, Osamu Muto, Michio Nakamura, Susumu Sogabe, Kentaro Sawada, Shintaro Nakano, Masataka Yagisawa, Tetsuhito Muranaka, Masayoshi Dazai, Miki Tateyama, Yoshimitsu Kobayashi, Sosuke Kato, Kazuteru Hatanaka, Yasuyuki Kawamoto, Satoshi Yuki, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Publikováno v:
Journal of Clinical Medicine
Volume 12
Issue 4
Pages: 1596
Volume 12
Issue 4
Pages: 1596
The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not es
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58106ec075031a2c6524330ed102f519
Autor:
Takashige Abe, Satomi Omotehara, Tomoko Mitsuhashi, Nobuo Shinohara, Junichi Sugita, Yoshito Komatsu, Ryuji Matsumoto, Hitoshi Shibuya, Kazunori Nagashima, Takehiko Katsurada, Takanori Teshima, Tetsuhito Muranaka, Mutsumi Nishida
Publikováno v:
SN Comprehensive Clinical Medicine. 2:215-221
Nivolumab is an immune checkpoint inhibitor (ICI), which is used for treatment of advanced malignancies. Diarrhea is a typical adverse effect of ICIs. Several endoscopic features of ICI-related colitis have been reported. Herein, we reported a case o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::621a927742be0e8dcafb760896a7a9af
https://doi.org/10.1007/s42399-019-00211-0
https://doi.org/10.1007/s42399-019-00211-0
Autor:
Masayoshi Dazai, Yuh Sakata, Kazuaki Harada, Isao Yokota, Ichiro Iwanaga, Hiroshi Nakatsumi, Masataka Yagisawa, Kentaro Sawada, Takayuki Ando, Ryusuke Matsumoto, R. Saito, Yasuyuki Kawamoto, Kazuteru Hatanaka, Miki Tateyama, M. Katagiri, Satoshi Yuki, Atsushi Sato, Yoshiaki Shindo, Tetsuhito Muranaka, Atsushi Ishiguro, Yoshito Komatsu, Ken Ito, Shintaro Nakano, Naoya Sakamoto
PurposeDysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c05628bffe9e3d0858060c0692b9efa3
https://doi.org/10.21203/rs.3.rs-1028179/v1
https://doi.org/10.21203/rs.3.rs-1028179/v1
Autor:
Kentaro Sawada, Yasushi Tsuji, Yoshito Komatsu, Susumu Sogabe, Masayoshi Dazai, Takuto Miyagishima, Yoshimitsu Kobayashi, Atsushi Ishiguro, Yasuyuki Kawamoto, Kazuaki Harada, Yuki Satoshi, Masataka Yagisawa, Tetsuhito Muranaka, Michio Nakamura, Yasuka Kikuchi
Purpose We previously reported that the periodic premedication of glucocorticoids during chemotherapy for gastrointestinal cancer (GIC) caused the reduction of bone mineral densities (BMD) (ESPRESSO-01). We conducted this study to evaluate the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55e97ae7e8d38c19829bb72a54dc46fc
https://doi.org/10.21203/rs.3.rs-993391/v1
https://doi.org/10.21203/rs.3.rs-993391/v1
Autor:
Tatsuya Yokoyama, Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Yoshito Komatsu
Publikováno v:
Annals of Oncology. 33:S477
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d521df7fcbdeebdfc60d0a2a4dd8228
https://doi.org/10.1016/j.annonc.2022.05.050
https://doi.org/10.1016/j.annonc.2022.05.050